Advisers said the CDC should not recommend the combined vaccine against measles, mumps, rubella, and varicella for young children.
The Centers for Disease Control and Prevention should stop recommending a specific combination measles shot to young children, the Advisory Committee on Immunization Practices (ACIP) said on Sept. 18.
The CDC should recommend only the measles, mumps, rubella (MMR) vaccine, and not the measles, mumps, rubella, varicella (MMRV) vaccine—which also prevents chicken pox—for children ages younger than 4, ACIP said.
The vote was 8 to 3. Dr. Robert Malone recused himself because he was in the past a paid expert for plaintiffs suing Merck, which manufactures MMR and MMRV vaccines.
If Jim O’Neill, the deputy health secretary and acting CDC director, accepts the recommendation, the CDC would change its vaccine schedule.
The CDC currently recommends either the MMRV vaccine, or the MMR vaccine along with a separate varicella shot, for the first dose against measles. It says the MMR vaccine is the preferred option for children ages 12 to 47 months, because the MMRV vaccine “is associated with a higher risk for fever and febrile seizures.”
About 85 percent of children receive the MMR and varicella vaccines, compared with 15 percent who receive an MMRV vaccine, for the first dose.
After MMR vaccination, there is about one additional febrile seizure per 3,000 to 4,000 of those vaccinated, compared with unvaccinated children. MMRV vaccination increases that risk twofold among young children, Dr. John Su, a CDC immunization official, said in a presentation. There’s no evidence of an increased risk following dose two of the MMRV vaccine among children ages 4 to 6, he said.
The second dose of a measles vaccine is recommended on the CDC schedule for children ages 4 to 6.
GlaxoSmithKline and Merck produce MMR vaccines cleared in the United States, but Merck also makes the only available MMRV vaccine. The companies did not respond to requests for comment by publication time.
“Any policy decision that compromises the clarity or consistency of vaccination guidance for MMRV has the potential to further diminish public confidence,” a Merck official told the panel before the vote, after referencing falling vaccination rates among kindergartners.
